Clinical efficacy of allograft bone combined with calcium phosphate bone powder in repairing bone defects of benign bone tumors

Abstract

Abstract Objective To observe the clinical efficacy of repairing bone defects of benign bone tumors with allograft bone combined with calcium phosphate bone powder. Methods Fifty-five patients with benign bone tumors admitted to our hospital from June 2020 to December 2022 were retrospectively analyzed, with a total of 55 bone defects. The patients were aged 10-64 (mean35±13.2) years old; according to the different bone graft materials used in reconstructing the bone defects, they were divided into the simple allograft bone group (simple group) and the allograft bone combined with calcium phosphate bone powder group (combined group). Among them, there were 25 cases in the combined group and 30 cases in the simple group. The basic preoperative data, operation time, intraoperative bleeding amount of the two groups were recorded, the postoperative incision infection, rejection and other adverse reactions of the two groups were counted, and the speed of bone healing, healing rate and residual bone defects of the two groups were observed by imaging. The Enneking standard was used to evaluate the limb function of the two groups at 12 months after surgery, and the Karnofsky functional status score (KPS) standard was used to evaluate the quality of life of the patients at 3, 6, and 12 months before and after surgery. Results All patients were followed up for 12-30 (13.45±5.18) months. All incisions healed at stage I. There were no complications such as non-healing of bone grafts, bone graft site fracture and articular surface collapse; no tumor recurrence was seen during the follow-up period. The 12-month postoperative healing rates of the combined group and the simple group were 97.5% and 92.5%, respectively, and the difference between the groups was not statistically significant (X2=1.136, P＞0.05); the healing time of the combined group was significantly shorter than that of the simple group, and the difference was statistically significant (t=4.280,P＜0.05); the rate of residual bone defects of the combined group was less than that of the simple group, but the difference was not statistically significant (X2=1.136, P＞0.05); the rate of bone defects of the combined group was less than that of the simple group, but the difference was not statistically significant (X2=1.136, P＞0.05); 12 months after surgery, the limb function rate of the combined group and the simple group was 96.0% and 93.3%, and the difference was not statistically significant when comparing between groups (X2=0.000,P＞0.05). The postoperative KPS scores of all patients were significantly higher than the preoperative ones, and the difference was statistically significant (P＜0.05). The KPS scores of the combined group were higher than those of the simple group at 6 months postoperatively, and the difference was statistically significant (X2=3.646,P＜0.05), whereas there was no statistically significant difference in the comparison of KPS scores of the two groups at 3 months postoperatively and 12 months postoperatively (P＞0.05). Conclusion Compared with allograft bone alone, allograft bone combined with calcium phosphate bone powder for repairing bone defects of benign bone tumors is more conducive to bone defect healing and good postoperative functional recovery.